HIND

Vyome Holdings, Inc.

• TipRanks·05/20 15:30

  Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Vyome Holdings (HIND)

• PUBT·05/12 20:04

  Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591

• TipRanks·05/12 16:18

  Vyome signs exclusive license agreement with Impetis

• PUBT·05/12 12:02

  Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors

• Reuters·05/12 12:00

  VYOME HOLDINGS INC - RECEIVES EXCLUSIVE LICENSE FOR SELECTIVE JAK 1/3 AND JAK1 INHIBITORS

• TipRanks·04/29 22:07

  Vyome Holdings Shareholders Tighten Capital Structure at Meeting

• PUBT·04/29 21:01

  Vyome Holdings shareholders approve cut in authorized common shares to 50 million

• TipRanks·04/23 17:35

  Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market

• TipRanks·04/22 12:37

  Vyome Holdings presents Phase 2 study results on VT-1953

• Benzinga·04/22 12:05

  Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting

• PUBT·04/22 12:03

  Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR

• TipRanks·04/06 12:44

  Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026

• Benzinga·04/06 12:06

  Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR

• Reuters·04/06 12:00

  Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026